The benefit and cost of prostate cancer early detection

CA: A Cancer Journal for Clinicians

Volumn 43, Issue 3, 1993, Pages 134-149

  Littrup, Peter J ^a,d   Goodman, Allen C ^b   Mettlin, Curits J ^c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Cancer Institute in Buffalo   (United States)

^d ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AMERICAN CANCER SOCIETY; BIOPSY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FALSE POSITIVE REACTIONS; HUMAN; MALE; MASS SCREENING; PALPATION; PROBABILITY; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECTUM; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 0027299543     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.43.3.134     Document Type: Article

References (32)

1. Cancer statistics, 1993
2. Prostate cancer in blacks: An update from the American College of Surgeons patterns of care studies
3. Trends in prostate care in the United States, 1974–1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer
4. Trends in patterns of care for prostatic cancer, 1974–1983: Results of surveys by the American College of Surgeons
5. The national survey of prostate cancer in the United States by the American College of Surgeons
6. Disease‐specific survival following routine prostate cancer screening by digital rectal examination
7. Economics of screening for carcinoma of the prostate
8. The American Cancer Society National Prostate Cancer Detection Project: Findings on the detection of early prostate cancer in 2425 men
9. Early prostate cancer: Diagnostic costs of screening transrectal US and digital rectal examination
10. Early detection of prostate cancer by routine screening
11. Is screening for breast cancer cost‐effective?
12. Sensitivity analysis in the cost‐effectiveness of breast cancer screening
13. Benefit‐cost analysis of screening: A comparison of tests for gonorrhea
14. Serum prostate specific antigen as pre‐screening test for prostate cancer
15. Measurement of prostate‐specific antigen in serum as a screening test for prostate cancer
16. Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
17. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients
18. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients
19. What do we gain from the sixth stool guaiac?
20. Defining and updating the American Cancer Society guidelines for the cancer‐related check‐up: Prostate and endometrial cancers
21. Detection of clinically significant prostate cancer by transrectal ultrasound‐guided systematic biopsies
22. Prostate cancer screening: Current trends and future implications
23. Predicted prostate specific antigen results using transrectal ultrasound gland volume: Differentiation of benign prostatic hyperplasia and prostate cancer
24. Prostate‐specific antigen levels in 1695 men without evidence of prostate cancer
25. Determination of prostate volume with transrectal US for cancer screening: Part 1. comparison with prostate‐specific antigen assays
26. The high 10‐year survival rate in patients with early, untreated prostate cancer
27. 125I implantation